Commentary: perioperative challenges: does smoking compromise high-flow nasal oxygen efficacy in obese men? a randomised controlled trial
Frontiers in Anesthesiology · 09.11.2026 · 5
DOI: 10.3389/fanes.2026.2016882 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Frontiers in Anesthesiology, online erschienen am 09.11.2026. Verfasst von María Claudia Niño und 3 weiteren Autor:innen. Die Arbeit nennt 6 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Wang et al. [1] compared safe apnoea duration in 30 obese male smokers and 30 never-smokers following 5 minutes of high-flow nasal oxygen (HFNO; 60 L/min, FiO₂ 1.0). They reported a shorter median safe apnoea duration among smokers than never-smokers [262.5 (IQR 138.5) vs. 373.5 (IQR 106.25) seconds; P=0.012]. The question is clinically relevant, and physiological data in obese patients who smoke are welcome. Nevertheless, several methodological issues affect how these findings should be interpreted, particularly regarding study design, the meaning of the primary endpoint, smoking exposure assessment, and causal inference.The reported study design is somewhat ambiguous. The article is described as a randomized controlled trial and the abstract labels it a prospective, randomized, controlled study; however, the Methods state that participants were divided into groups according to their pre-existing smoking status, and no random allocation procedure relevant to the smoking-status comparison is describedThus, regardless of whether randomization occurred for another aspect of the protocol, the comparison between smokers and neversmokers is observational in nature. For this comparison, observational reporting principles such as STROBE [2], rather than CONSORT 2025 [3], may therefore be more applicable unless the randomization procedure relevant to smoking status is further clarified. This distinction is not merely semantic. With only 30 participants per group and no adjusted analysis, potential determinants of desaturation time-including body mass index, neck circumference, obstructive sleep apnoea risk, age, and other physiological characteristics-may remain imbalanced. The absence of statistically significant baseline differences in a small sample does not demonstrate equivalence between groups. Therefore, the observed association between smoking status and safe apnoea duration should not be interpreted as establishing a causal effect of smoking.The title asks whether smoking compromises the efficacy of HFNO, yet both groups received the same 5minute HFNO preoxygenation protocol and there was no alternative preoxygenation strategy or group without HFNO. Consequently, the study does not directly compare the efficacy of HFNO with another oxygenation strategy.The protocol also warrants precise interpretation. Oxygen delivery was discontinued 90 seconds after rocuronium administration; however, the exact onset of apnoea relative to this point was not explicitly reported. Moreover, the recorded "apnoeic oxygenation time" was defined as the interval from SpO₂ 100% to SpO₂ 92%, rather than explicitly from the onset of apnoea to desaturation. The primary endpoint therefore reflects the safe desaturation interval under the reported protocol, incorporating standardized HFNO preoxygenation and the subsequent induction period, but it should not be assumed to represent a precisely defined period of ongoing HFNO-mediated apnoeic oxygenation. This distinction is supported by the arterial blood gas results: PaO₂ after preoxygenation was high in both groups and did not differ significantly (474.7 vs. 446.8 mmHg). A more precise interpretation would therefore be that safe apnoea duration differed according to smoking status after standardized HFNO preoxygenation, rather than that smoking reduced the comparative efficacy of HFNO. By contrast, randomized comparisons between HFNO and alternative oxygenation strategies, such as the study by Schutzer-Weissmann et al. [4], are better suited to questions of comparative HFNO efficacy.The authors appropriately acknowledge that conventional pulse oximetry may overestimate arterial oxygenation in the presence of elevated carboxyhaemoglobin (COHb), which may occur in active smokers [5]. Because the primary outcome depends on the time to an SpO₂ threshold of 92%, this represents a plausible measurement limitation. This issue is central because the primary outcome is entirely determined by the time to an SpO₂ threshold of 92%.The exposure definition introduces additional uncertainty. Smokers were described as individuals who had "continued smoking up to at least 14 days prior to surgery," a formulation that does not clearly establish the interval between the last cigarette and surgery. Since COHb concentrations decline after smoking cessation, the interval from the last cigarette would be relevant for assessing whether COHbrelated measurement error was likely at the time of surgery. If co-oximetry was available, reporting COHb and directly measured arterial oxygen saturation would help clarify this issue. Non-invasive pulse cooximetry may also provide useful complementary information in future studies [6].The statistical reporting could likewise be strengthened. The primary outcome was summarized as medians and compared using the Mann-Whitney U test, but only a P value was reported. An effect estimate with a 95% confidence interval, together with an adjusted analysis accounting for clinically relevant covariates such as BMI, neck circumference, STOP-Bang score, and age, would better quantify the association.The participant flow also warrants clarification. Figure 1 reports exclusion of one smoker because "SpO₂ drops to 90%," whereas the text states that one patient was excluded because oxygen saturation was below 90%. If this occurred during the study apnoea period, exclusion would be directly related to the primary outcome and could bias the observed group difference; a sensitivity analysis including this participant would therefore be informative.Finally, the reported difference in postoperative nausea and vomiting (6/30 vs. 1/30; P=0.044) is based on few events and was not adjusted for multiple secondary comparisons. It should therefore be regarded as exploratory.The finding of a shorter safe apnoea duration among obese male smokers is clinically interesting, but statements that smoking "unequivocally" confers a disadvantage or provides a "clear mandate" for altered airway management should be interpreted cautiously given the single-centre sample of 60 participants and the observational nature of the smoking-status comparison. The original article itself uses both expressions when interpreting its findings. Smoking cessation is undoubtedly appropriate perioperative practice, but its benefit cannot be inferred from this study because cessation was not evaluated as an intervention.We therefore suggest reframing the principal conclusion as an association between smoking status and shorter safe apnoea duration after standardized HFNO preoxygenation. Clarification of the randomization procedure, the timing of apnoea relative to oxygen discontinuation, the interval since the last cigarette, availability of COHb measurements, participant exclusions, and adjusted effect estimates would substantially improve interpretability. Future randomized studies comparing preoxygenation strategies and stratifying participants by objectively measured smoking exposure and COHb could more directly determine whether smoking modifies the effectiveness of HFNO.
Zitieren
APA
Niño, M. C., Romero-Fragozo, A., Solano-Salazar, A., & Mejía, J. A. (2026). Commentary: perioperative challenges: does smoking compromise high-flow nasal oxygen efficacy in obese men? a randomised controlled trial. Frontiers in Anesthesiology, 5. https://doi.org/10.3389/fanes.2026.2016882
Vancouver
Niño MC, Romero-Fragozo A, Solano-Salazar A, Mejía JA. Commentary: perioperative challenges: does smoking compromise high-flow nasal oxygen efficacy in obese men? a randomised controlled trial. Frontiers in Anesthesiology. 2026;5. doi:10.3389/fanes.2026.2016882
BibTeX
@article{Nio2026,
author = {Niño, María Claudia and Romero-Fragozo, Alejandra and Solano-Salazar, Ana and Mejía, Juan Armando},
title = {Commentary: perioperative challenges: does smoking compromise high-flow nasal oxygen efficacy in obese men? a randomised controlled trial},
journal = {Frontiers in Anesthesiology},
year = {2026},
volume = {5},
doi = {10.3389/fanes.2026.2016882}
}
EUVIMED